Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 5;15(1):210.
doi: 10.1007/s12672-024-01068-z.

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Xinyi Jian  1   2   3 , Jie Cha  3 , Zhijuan Lin  3 , Siting Xie  3 , Yueting Huang  3 , Yun Lin  3 , Haijun Zhao  4 , Bing Xu  5   6   7 , Yiming Luo  8   9   10
Affiliations

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Xinyi Jian et al. Discov Oncol. .

Abstract

Background: The treatment of myeloid sarcoma (MS) is challenging and has not markedly improved patient prognosis. The introduction of venetoclax (VEN) has changed the treatment of MS, and venetoclax-based therapy has been described as very promising in several case reports.

Methods: In this retrospective study, we analyzed the treatment outcomes of 14 patients with MS treated with venetoclax-based therapy at The First Affiliated Hospital of Xiamen University from January 2020 to October 2023 RESULTS: The cohort consisted of 7 (50%) women and 7 (50%) men with an average age of 37.5 years. Four patients (28.6%) had isolated MS de novo, 2 (14.2%) were diagnosed synchronously with AML, and 8 (57.2%) had isolated extramedullary relapse. The most common sites for MS in our cohort were the skin and lung, followed by the spinal canal, soft tissue, bone and kidney. Five patients were affected at more than three sites. Nine patients received VEN in combination with azacytidine, and 5 patients received VEN in combination with other agents. The median number of venetoclax therapies administered was 2 cycles (range: 1-10 cycles). A response was observed in all patients included in the study, with 8 patients (57.2%) achieving a CR and 3 patients (21.4%) achieving a PR, corresponding to an ORR (including CR and PR) of 78.6%. The median follow-up time for all patients was 13 months (range 1-44 months), and the 1 year OS for all patients was 67.7%.

Conclusions: Venetoclax-based therapy shows excellent efficacy and safety in MS patients in the "real world" at a single institution, and a corresponding prospective study is needed to verify this conclusion.

Keywords: BCL-2; Extramedullary disease; Myeloid sarcoma; Prognosis; Treatment; Venetoclax.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Swimmer plot of 14 patients treated with VEN-based therapies
Fig. 2
Fig. 2
The survival probability of patients after diagnosis of MS
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19. doi: 10.1038/s41375-022-01613-1. - DOI - PMC - PubMed
    1. Wilson CS, Medeiros LJ. Extramedullary manifestations of myeloid neoplasms. Am J Clin Pathol. 2015;144(2):219–239. doi: 10.1309/AJCPO58YWIBUBESX. - DOI - PubMed
    1. Bakst RL, Tallman MS, Douer D, et al. How I treat extramedullary acute myeloid leukemia. Blood. 2011;118(14):3785–3793. doi: 10.1182/blood-2011-04-347229. - DOI - PubMed
    1. Campidelli C, Agostinelli C, Stitson R, et al. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132(3):426–437. doi: 10.1309/AJCP1ZA7HYZKAZHS. - DOI - PubMed
    1. Messager M, Amielh D, Chevallier C, et al. Isolated granulocytic sarcoma of the pancreas: a tricky diagnostic for primary pancreatic extramedullary acute myeloid leukemia. World J Surg Oncol. 2012;10:13. doi: 10.1186/1477-7819-10-13. - DOI - PMC - PubMed

LinkOut - more resources